Search results
Results from the WOW.Com Content Network
Rilpivirine and cabotegravir were approved for medical use in the European Union in December 2020, as two separate medications. [11] [12] In January 2021, the U.S. Food and Drug Administration (FDA) granted the approval of Cabenuva to ViiV Healthcare. [4] [8] The combination was approved for medical use in Australia in February 2021. [14] [15]
Cabotegravir is recommended in combination with safer sexpractices for pre-exposure prophylaxis to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing ...
Cabotegravir in combination with rilpivirine is indicated for the treatment of human immunodeficiency virus type-1 (HIV-1) in adults. [1] [7] The combination injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/mL) with their current antiretroviral treatment, and when the virus has not developed resistance to ...
HPTN 083 is a 2016 clinical trial which compares cabotegravir injections with oral use of Emtricitabine/tenofovir as pre-exposure prophylaxis ("PrEP") for prevention of HIV/AIDS. The study seeks to test injectable PrEP as a way to remedy adherence for many patients on a daily pill regimen.
Treatment of people aged twelve years of age and older with solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy [2]
Australia approved on Thursday a social media ban for children aged under 16 after an emotive debate that has gripped the nation, setting a benchmark for jurisdictions around the world with one of ...
Three clinical trials found that Beyfortus reduces the risk of RSV in infants and children under 2 years old by 70 to 75%. Beyfortus is expected to be available in the U.S. before the upcoming ...
The High Court (Administrative Court) ruling, [3] [4] which was overturned on appeal, said that it was unlikely that a child under the age of 16 could be Gillick competent to consent to puberty blocking treatment. The court also said that "[in] respect of young persons aged 16 and over… we recognise that clinicians may well regard these as ...